Hiroshi Miyake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroshi Miyake has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Akio Mizutani
Chordia Therapeutics Inc., Fujisawa, Japan
22 shared publications - Daisuke Morishita
Chordia Therapeutics Inc., Fujisawa, Japan
22 shared publications - Eiji Takahara
Chordia Therapeutics Inc., Fujisawa, Japan
22 shared publications - Hirokazu Tozaki
Chordia Therapeutics Inc., Fujisawa, Japan
22 shared publications - Jun Sato
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
22 shared publications - Kan Yonemori
National Cancer Center Hospital, Tokyo, Japan
22 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Representativeness of Study Participants.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Representativeness of Study Participants.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Biomarker analysis of tissue samples from patients with solid tumors.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Biomarker analysis of tissue samples from patients with solid tumors.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
OS and PFS of all patients with solid tumors.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
OS and PFS of all patients with solid tumors.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Expanded previous therapies for patients with solid tumors.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Expanded previous therapies for patients with solid tumors.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table 4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
PD parameters of patients with solid tumors.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
PD parameters of patients with solid tumors.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
All TRAEs occurring in ≥10% of patients with solid tumors.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
All TRAEs occurring in ≥10% of patients with solid tumors.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
PK and PD of rogocekib. Mean plasma rogocekib concentrations following oral administration are shown (A). Error bars represent standard deviation (S.D.) values for each time point. Mean fold changes in THAP9-AS1 (B) and S6K (C) RNA markers following rogocekib administration are shown. Fold changes are presented as values relative to each patient’s predose baseline; accordingly, the predose value corresponds to a fold change of 1.0. Error bars represent S.D. values for each time point. For both PK and PD graphs, data from patients with a dose of 70 mg twice weekly from cohorts A and D have been combined for presentation purposes.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
PK and PD of rogocekib. Mean plasma rogocekib concentrations following oral administration are shown (A). Error bars represent standard deviation (S.D.) values for each time point. Mean fold changes in THAP9-AS1 (B) and S6K (C) RNA markers following rogocekib administration are shown. Fold changes are presented as values relative to each patient’s predose baseline; accordingly, the predose value corresponds to a fold change of 1.0. Error bars represent S.D. values for each time point. For both PK and PD graphs, data from patients with a dose of 70 mg twice weekly from cohorts A and D have been combined for presentation purposes.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
ORR of all patients with solid tumors and ovarian cancer.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
ORR of all patients with solid tumors and ovarian cancer.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
PK parameters of patients with solid tumors.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
PK parameters of patients with solid tumors.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Characteristics of patients in dose escalation and expansion cohorts.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors
Characteristics of patients in dose escalation and expansion cohorts.